Clinical application progress of bendamustine in lymphocytic malignancy / 白血病·淋巴瘤

ABSTRACT

Bendamustine hydrochloride is a bifunctional alkylating agent with clinical activity to a number of cancers.Bendamustine,an emerging nitrogen mustards anticancer agent,can improve tolerability without sacrificing clinical activity.Although bendamustine has been used widely for more than 40 years,it was not systematically studied in lymphoproliferative disorders until the 1990s.Bendamustine molecule is more stable than the molecules of other alkylators,and it can cause more extensive and more durable damage to DNA.Unlike other alkylating agents,primary targets of bendamustine are based on excision repair pathways rather than mismatch repair pathways,and it activates DNA damage stress responses,induces apoptosis,inhibits mitotic checkpoints,and induces mitotic catastrophe.This paper will review the role of bendamustine in chronic lymphoblastic leukemia(CLL),indolent non-Hodgkin's lymphoma (NHL),diffuse large B-cell lymphoma (DLBCL),mantle cell lymphoma (MCL),peripheral T-cell lymphoma (PTCL),and Hodgkin' s lymphoma (HL).